Gland Pharma secures USFDA okay for Norepinephrine Bitartrate in 5% Dextrose Injection Bags
This Product is indicated to raise blood pressure in adult patients with severe, acute hypotension.;
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-08-12 09:00 GMT | Update On 2025-08-12 09:00 GMT
Advertisement
Hyderabad: Gland Pharma Limited, a generic injectable & ophthalmic focused pharmaceutical company, has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) filed through its partner for Norepinephrine Bitartrate in 5% Dextrose Injection, 4 mg/250 mL (16 mcg/mL) and 8 mg/250 mL (32 mcg/mL) Single-Dose Bags.
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD),NOREPINEPHRINE BITARTRATEIN 5% DEXTROSE of Baxter Healthcare Corp.
This Product is indicated to raise blood pressure in adult patients with severe, acute hypotension.
We are the exclusive First-to-File and is eligible for 180 days of generic drug exclusivity.
Read also: Gland Pharma Pashamylaram facility receives GMP compliance certificate from Danish Medicines Agency
According to IQVIA, the product had US sales of approximately USD 55 million for the twelve months ending June 2025.
In June, the company also received USFDA approval for its ANDA for Angiotensin II Acetate Injection 2.5 mg/mL, used for increasing the blood pressure in adults with septic or other distributive shock.
Gland Pharma was established in 1978 in Hyderabad and has grown over the years from a contractmanu facturer of small-volume liquid parenteral products to become one of the largest injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It operates primarily under a business-to-business (B2B) model and has an excellent track record in developing, manufacturing, and marketing sterile injectables. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. It also enjoys the distinction of having pioneered Heparin technology in India.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.